Shandong Xinhua Pharmaceutical Company Limited (FRA:XIN)
Germany · Delayed Price · Currency is EUR 0.7300
-0.0100 (-1.35%)
Last updated: Jan 28, 2026, 8:07 AM CET
FRA:XIN Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 8,352 | 8,324 | 7,956 | 7,295 | 6,360 | 5,949 |
Other Revenue | 142.44 | 142.44 | 144.78 | 207.82 | 200.54 | 56.85 |
| 8,495 | 8,466 | 8,101 | 7,503 | 6,560 | 6,006 | |
Revenue Growth (YoY) | 1.89% | 4.51% | 7.97% | 14.37% | 9.23% | 7.13% |
Cost of Revenue | 6,795 | 6,481 | 5,779 | 5,515 | 4,824 | 4,244 |
Gross Profit | 1,699 | 1,985 | 2,321 | 1,988 | 1,736 | 1,762 |
Selling, General & Admin | 817.34 | 1,017 | 1,287 | 1,106 | 929.12 | 943.96 |
Research & Development | 386.62 | 413.18 | 419.24 | 345.66 | 341.37 | 298.35 |
Other Operating Expenses | 47.49 | 35.88 | 92.18 | 65.31 | 59.27 | 60.28 |
Operating Expenses | 1,261 | 1,475 | 1,809 | 1,522 | 1,332 | 1,303 |
Operating Income | 438.55 | 510.63 | 512.15 | 465.87 | 403.67 | 458.77 |
Interest Expense | -40.38 | -39.74 | -41.15 | -49.71 | -53.1 | -59.76 |
Interest & Investment Income | 14.77 | 20.96 | 21.88 | 18.83 | 16.79 | 11.58 |
Currency Exchange Gain (Loss) | 19.09 | 19.09 | 15.42 | 10.53 | -4.18 | -24.78 |
Other Non Operating Income (Expenses) | -4.27 | -3.41 | -2.72 | -3.38 | -2.45 | -4.46 |
EBT Excluding Unusual Items | 427.76 | 507.53 | 505.59 | 442.15 | 360.72 | 381.35 |
Gain (Loss) on Sale of Assets | 1.4 | 1.42 | 8.73 | 5.54 | 2.07 | 2.49 |
Asset Writedown | -7.1 | -5.12 | -10.29 | -2.61 | -1.88 | -4.43 |
Other Unusual Items | 24.67 | 29.82 | 28.65 | 26.7 | 60.32 | 32.23 |
Pretax Income | 446.73 | 533.65 | 532.69 | 471.77 | 421.23 | 411.64 |
Income Tax Expense | 48.56 | 46.94 | 26.58 | 45.66 | 59.16 | 64.52 |
Earnings From Continuing Operations | 398.17 | 486.71 | 506.11 | 426.11 | 362.07 | 347.11 |
Minority Interest in Earnings | -16.01 | -16.69 | -9.59 | -15.05 | -13.53 | -22.25 |
Net Income | 382.16 | 470.02 | 496.51 | 411.06 | 348.55 | 324.86 |
Net Income to Common | 382.16 | 470.02 | 496.51 | 411.06 | 348.55 | 324.86 |
Net Income Growth | -14.81% | -5.33% | 20.79% | 17.94% | 7.29% | 8.30% |
Shares Outstanding (Basic) | 685 | 682 | 674 | 661 | 627 | 622 |
Shares Outstanding (Diluted) | 691 | 688 | 692 | 671 | 627 | 627 |
Shares Change (YoY) | -0.13% | -0.54% | 3.20% | 6.93% | -0.02% | 0.86% |
EPS (Basic) | 0.56 | 0.69 | 0.74 | 0.62 | 0.56 | 0.52 |
EPS (Diluted) | 0.55 | 0.68 | 0.72 | 0.61 | 0.56 | 0.52 |
EPS Growth | -15.48% | -5.56% | 18.03% | 9.75% | 6.89% | 8.33% |
Free Cash Flow | 268.97 | 155.19 | -59.85 | 513.48 | 9.89 | 140 |
Free Cash Flow Per Share | 0.39 | 0.23 | -0.09 | 0.77 | 0.02 | 0.22 |
Dividend Per Share | 0.250 | 0.275 | 0.250 | 0.200 | 0.150 | 0.150 |
Dividend Growth | -9.09% | 10.00% | 25.00% | 33.33% | - | 25.00% |
Gross Margin | 20.01% | 23.45% | 28.66% | 26.50% | 26.46% | 29.33% |
Operating Margin | 5.16% | 6.03% | 6.32% | 6.21% | 6.15% | 7.64% |
Profit Margin | 4.50% | 5.55% | 6.13% | 5.48% | 5.31% | 5.41% |
Free Cash Flow Margin | 3.17% | 1.83% | -0.74% | 6.84% | 0.15% | 2.33% |
EBITDA | 995.96 | 1,049 | 1,026 | 952.48 | 840.2 | 842.97 |
EBITDA Margin | 11.72% | 12.40% | 12.67% | 12.70% | 12.81% | 14.04% |
D&A For EBITDA | 557.41 | 538.84 | 514.09 | 486.61 | 436.53 | 384.2 |
EBIT | 438.55 | 510.63 | 512.15 | 465.87 | 403.67 | 458.77 |
EBIT Margin | 5.16% | 6.03% | 6.32% | 6.21% | 6.15% | 7.64% |
Effective Tax Rate | 10.87% | 8.80% | 4.99% | 9.68% | 14.04% | 15.68% |
Revenue as Reported | 28.45 | - | - | 7,503 | - | 6,006 |
Advertising Expenses | - | 7.46 | 8.95 | 8.18 | 11.33 | 12.84 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.